Business
Update on Phase IIa Clinical
Update on Phase IIa Clinical.
About this update from Immupharma Plc
[{"type":"text","content":"\n RNS Number : 6358U Immupharma PLC 19 October 2010 \n \n\n\n\n\n\nFor Immediate Release\n\n\n19 October 2010\n\n\n\n\n \nImmuPharma plc\n \nUpdate on Phase IIa Clinical Trial with Cancer Compound IPP-204106\n \nImmuPharma plc (LSE:IMM) (\"Immupharma\" or the \"Company\" or the \"Group\"), the specialist discovery and development pharmaceutical company is pleased to announce that at today's analyst briefing, Dr Robert Zimmer, Chief Scientific Officer, will give the following update on ImmuPharma's exciting Cancer programme IPP-204106, the summary of which is detailed below:\n \n Key Highlights:\n \n· Dose escalating open label study commenced in patients with at least one treatment failure according to standard regulatory guidelines;\n· The study was designed to show safety and tolerability and assess the maximum tolerated dose;\n· Patients are dosed with an initial dose of 40 mg/sq.m. or 1 mg/kg and if stabilisation or improvement occurs, then patients continue treatment for an additional 4 sessions; \n· 6 patients have been dosed so far, suffering from either breast cancer, lung cancer and bladder cancer and all with metastasis;\n· No serious drug-related adverse events have so far been reported; and\n· 2 patients have already been rated as having stabilised disease.\n \nImmuPharma plans to file a US IND in the next few months and to commence a Phase IIb programme the first half of 2011 in patients with metastatic melanoma, glioblastoma, hormone-resistant prostate cancer and pancreatic cancer, which will be confirmed by additional preclinical data.\n \n \nFor further information, please contact:\n \nImmuPharma PLC:\nDr Robert Zimmer, President & Chief Scientific Officer + 33 389 32 76 50\nDimitri Dimitriou, Chief Executive Officer +44 20 7152 4080\nRichard Warr, Chairman &n...